Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Predictive biomarkers of response to VenBd in R/R MM

Michael O’Dwyer • 7 Dec 2019
ASH 2019
Multiple Myeloma Bortezomib Dexamethasone Venetoclax
BELLINI

Michael O’Dwyer, MD, PhD, National University of Ireland, Galway, Ireland, discusses the biomarker analysis from the phase III BELLINI study (NCT02755597) of venetoclax in combination with bortezomib and dexamethasone (VenBd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). This revealed that VenBd shows significant efficacy in patients harboring either t(11;14) or with tumor cells expressing high levels of BCL2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Michael O’Dwyer

3:31
Genomic and transcriptomic analysis of R/R myeloma in the Phase III BELLINI study
Michael O’Dwyer • 30 Nov 2020
5:14
Current myeloma cellular therapy landscape and horizon scan
Michael O’Dwyer • 30 Nov 2020
2:01
Cellular therapy: NK-cells as a model
Michael O’Dwyer • 21 May 2020
5:14
NK-cell enhancement: TRAIL variant
Michael O’Dwyer • 18 May 2020

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals